Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study.

Adrian Segura Diaz, Lucia Perez Lamas, Ruth Stuckey, alberto Alvarez-Larran, María Alicia Senin, Elvira Mora Casterá, Paula Sastre, Maria Laura Fox, Irene Pastor Galan, María Teresa Gómez Casares, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente, Regina Garcia Delgado, Míriam Vara Pampliega, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Abel Domingo, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero-Portero, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar-Franco, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Davila Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Teresa Cobo, Aitor Abuin Blanco, Francisco Pérez, Maria José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez

Blood (2025) 146 (Supplement 1): 3808.

https://doi.org/10.1182/blood-2025-3808

Published: 2025

Journal Articles

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Almudena Zaratiegui Vergara, Gonzalo Carreño, Francisca Ferrer Marin, Blanca Xicoy, María Teresa Gómez Casares, Fermin Sanchez-Guijo, M Concepción Ruiz Nuño, Santiago Osorio Prendes, Raquel De Paz, Ana Isabel Rosell Mas, Elvira Mora Casterá, María Alicia Senin, Juan Carlos Hernandez Boluda, Rosa Ayala Diaz, Valentín García Gutiérrez, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2025-3778

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

Leticia Morales Espino, Ruth Stuckey, Antonio Molinés Honrubia, Adrián Segura-Díaz, Santiago Sánchez-Sosa, Sunil Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, Maria Tapia Torres, Yanira Florido, Cristina Bilbao-Sieyro, María Teresa Gómez Casares

Blood (2024) 144 (Supplement 1): 3159.

https://doi.org/10.1182/blood-2024-200651

Published: 2024

Journal Articles

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas, Adrian Segura Diaz, Regina García Delgado, Alberto Alvarez-Larran, María Alicia Senin, Elvira Mora, Maria Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente Alegre, Míriam Vara, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Maria Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, María José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2024-200698

Published: 2024

Journal Articles

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Blood (2024) 144 (Supplement 1): 241.

https://doi.org/10.1182/blood-2024-198336

Published: 2024

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Biological Factors Associated with Treatment-Free Remission in Clinical Practice: Data from the Canarian Registry of CML

Ruth Stuckey, Santiago Sánchez-Sosa, Paula Estupiñan Cabrera, Cristian Cruz Rodríguez, Adrián Segura-Díaz, Sunil Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, Maria Tapia Torres, Cristina Bilbao-Sieyro, Maria Teresa Gómez-Casares

Blood (2023) 142 (Supplement 1): 6362.

https://doi.org/10.1182/blood-2023-188714

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Blood (2023) 142 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2023-188875

Published: 2023

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Quantification of JAK2 V167F in Patients with Myeloproliferative Neoplasms: Comparison of NGS and Digital PCR with Quantitative PCR

Ruth Stuckey, Guillermo Santana, Yanira Florido, Adrián Segura-Díaz, Maria Teresa Gómez-Casares, Cristina Bilbao-Sieyro

Blood (2023) 142 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2023-188510

Published: 2023

Journal Articles

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 12245–12247.

https://doi.org/10.1182/blood-2022-168900

Published: 2022

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Valentín García Gutiérrez, Luis Felipe Casado Montero, Raquel de Paz, María Teresa Gómez-Casares, Angel Ramírez Payer, Rosa Ayala, Raul Perez Lopez, Francisca Ferrer Marin, Blanca Xicoy, Juan Luis Steegmann, Fermin Sanchez-Guijo, Joaquín Martínez-López

Blood (2022) 140 (Supplement 1): 12206–12207.

https://doi.org/10.1182/blood-2022-165998

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study.

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Biological Factors Associated with Treatment-Free Remission in Clinical Practice: Data from the Canarian Registry of CML

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Quantification of JAK2 V167F in Patients with Myeloproliferative Neoplasms: Comparison of NGS and Digital PCR with Quantitative PCR

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only